Published in Int J Cancer on October 20, 2002
Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev (2008) 5.25
Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol (2012) 3.40
Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov (2013) 2.16
Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev (2011) 1.97
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (2011) 1.81
Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol (2007) 1.57
Jarid1b targets genes regulating development and is involved in neural differentiation. EMBO J (2011) 1.50
Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer (2011) 1.47
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res (2010) 1.18
The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics (2009) 1.14
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
Histone demethylases and cancer. Adv Cancer Res (2009) 1.05
Chromatin as an oxygen sensor and active player in the hypoxia response. Cell Signal (2011) 1.05
Novel gene expression patterns along the proximo-distal axis of the mouse embryo before gastrulation. BMC Dev Biol (2007) 1.05
Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes. Genes Dev (2013) 0.99
The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell (2014) 0.97
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun (2010) 0.97
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun (2010) 0.96
Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci U S A (2010) 0.94
An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol (2006) 0.90
PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis. Chromosoma (2003) 0.88
Chromatin and oxygen sensing in the context of JmjC histone demethylases. Biochem J (2014) 0.87
Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem (2014) 0.86
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer (2016) 0.85
MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One (2014) 0.84
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia. J Biol Chem (2015) 0.82
Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes. J Biol Chem (2014) 0.81
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Tumour Biol (2015) 0.81
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann N Y Acad Sci (2010) 0.80
Escape from Mitotic Arrest: An Unexpected Connection Between Microtubule Dynamics and Epigenetic Regulation of Centromeric Chromatin in Schizosaccharomyces pombe. Genetics (2015) 0.79
Histone demethylase lysine demethylase 5B in development and cancer. Oncotarget (2016) 0.79
Molecular pathways involved in pregnancy-induced prevention against breast cancer. Front Endocrinol (Lausanne) (2014) 0.78
Impairment of preimplantation porcine embryo development by histone demethylase KDM5B knockdown through disturbance of bivalent H3K4me3-H3K27me3 modifications. Biol Reprod (2015) 0.78
Crystallization and preliminary crystallographic analysis of a PHD domain of human JARID1B. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.78
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines. Int J Clin Exp Pathol (2015) 0.78
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. J Exp Clin Cancer Res (2016) 0.76
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines (2017) 0.76
The KDM5 family is required for activation of pro-proliferative cell cycle genes during adipocyte differentiation. Nucleic Acids Res (2016) 0.75
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol (2017) 0.75
Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death Dis (2016) 0.75
Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther (2016) 0.75
Kinetochore Components Required for Centromeric Chromatin Assembly Are Impacted by Msc1 in Schizosaccharomyces pombe. Genetics (2017) 0.75
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res (2008) 2.96
Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res (2006) 2.30
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem (2005) 1.59
Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol (2007) 1.57
Human PLU-1 Has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9. J Biol Chem (2003) 1.50
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology (2005) 1.50
Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res (2010) 1.41
Joyce Taylor-Papadimitriou. Interview by Fiona Watt. J Cell Sci (2004) 1.39
Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology (2006) 1.35
MUC1 immunotherapy. Immunotherapy (2010) 1.34
PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol (2011) 1.31
Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer (2007) 1.30
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol (2008) 1.27
Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res (2007) 1.26
Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol (2007) 1.24
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res (2011) 1.20
Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J Cell Mol Med (2012) 1.19
Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res (2011) 1.17
Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J (2003) 1.15
Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology (2010) 1.14
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab (2004) 1.01
Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol (2012) 0.98
Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. Int J Oncol (2004) 0.97
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J (2009) 0.97
ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front Biosci (Elite Ed) (2011) 0.95
Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Mol Ther (2013) 0.93
Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I. J Immunol (2007) 0.92
Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol (2005) 0.92
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother (2011) 0.91
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology (2003) 0.90
Technical challenges facing therapeutic cancer vaccines. Curr Opin Drug Discov Devel (2008) 0.90
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer (2014) 0.89
PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis. Chromosoma (2003) 0.88
NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3. Eur J Biochem (2002) 0.86
Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer. Gene Expr Patterns (2002) 0.86
Alternative TFAP2A isoforms have distinct activities in breast cancer. Breast Cancer Res (2011) 0.85
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J Biomed Biotechnol (2003) 0.85
A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription in vitro and in vivo. Int J Oncol (2004) 0.84
Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer. J Biol Chem (2012) 0.84
A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase. Glycobiology (2004) 0.84
Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer. Mech Dev (2002) 0.84
Gene expression changes induced by a recombinant E1-/E3- adenovirus type 5 vector in human mammary epithelial cells. Intervirology (2005) 0.84
Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol (2005) 0.83
Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol (2014) 0.82
Transforming growth factor-β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells. Biotechnol Bioeng (2011) 0.81
Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells. J Immunol Methods (2004) 0.80
Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasm. BMC Biotechnol (2011) 0.80
Characterization of integrin and anchorage dependence in mammary epithelial cells following c-erbB2-induced epithelial-mesenchymal transition. Tumour Biol (2005) 0.79
Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother (2002) 0.79
Tripartite immune cell co-operation in the Bacillus Calmette Guérin-induced activation of γδ T cells. Immunol Cell Biol (2013) 0.78
Rab3D is critical for secretory granule maturation in PC12 cells. PLoS One (2013) 0.78
Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. Int J Cancer (2004) 0.78
Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing. Immunology (2014) 0.76
Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles. Viral Immunol (2007) 0.76
Multiple telomeric aberrations in a telomerase-positive leukemia patient. Cancer Genet Cytogenet (2002) 0.75
T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients. Int J Cancer (2011) 0.75